Le Lézard
Classified in: Health
Subject: NEW PRODUCTS/SERVICES

Tilray Brands Launches XMG Zero, a New ?Better for You' Cannabis Beverage


TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced a bold new range of cannabis-infused beverages from XMG, under two of its sub-brands: XMG Zero and XMG Plus ("XMG+"). XMG Zero, an extension of XMG's original core line, now offers two new THC beverages: Cream Soda Zero and Orange Soda Zero. XMG+, a boosted version of XMG original, focuses on high CBG and guarana extract (for naturally occurring caffeine), while revealing their new Banana Brain Freeze and Iced Rocket Berry flavours. Recognized for their diverse offerings and unique profiles including a variety of THC and CBG ratios, XMG is reshaping the cannabis beverage market with unparalleled variety and quality. 

XMG has been the #1 brand in cannabis-infused beverages with the largest product line available in Canada1, serving as a top trusted brand in the cannabis beverage space with go-to options consumers know and love.

XMG'S latest innovations from XMG Zero include:

XMG's latest innovations from its XMG+ line, include: 

XMG continues to dominate the ready-to-drink cannabis beverage space with its new releases from XMG Zero and XMG+, providing consumers with a variety of flavours and cannabinoid options to explore all summer long.

To find XMG's most recent thirst quenchers, and to keep up with the latest news from XMG, follow @findyourXMG on social. 

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with four distinct and complementary business segments including medical and adult-use cannabis, medical distribution, wellness foods, and beverage-alcohol. Tilray Brands is on a mission to change people's lives for the better ? one person at a time - by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis and consumer products company in the world with a portfolio of innovative, high-quality, and beloved brands that address the needs of the consumers, customers, and patients we serve. A pioneer in cannabis research, cultivation, and distribution, today Tilray Brands' unprecedented and diversified production platform supports a portfolio of best-in-class brands in over 20 countries including comprehensive adult-use and medical cannabis offerings, hemp-based foods, and craft beverages across North America, Europe, Australia, and Latin America. 

For more information on Tilray Brands, visit Tilray Brands, Inc. and follow @Tilray on Instagram, Twitter, Facebook, and LinkedIn. 

Forward-Looking Statements
 

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, "forward-looking statements") under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements can be identified by words such as "forecast," "future," "should," "could," "enable," "potential," "contemplate," "believe," "anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will," "would" and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. 

Contacts: 
Media: 
Kaitlin Macapagal 
[email protected]

Investors 
Raphael Gross 
203-682-8253 
[email protected] 

1 Source: Hifyre Data, National Beverage Sales, March 2024

 



These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: